Ultragenyx to seek accelerated approval for rare disease gene therapy
Ultragenyx moved one step closer to establishing a new surrogate biomarker for accelerated approval in rare disease gene therapies.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
